Jiangsu Vcare and Geneseeq Form Strategic Partnership for NTRK Companion Diagnostics
Published Time:
2024-07-02 17:28
Source:
On July 2, 2024, Jiangsu Vcare and Geneseeq signed a strategic cooperation agreement in Nanjing’s Jiangbei New District. The collaboration will focus on the joint development and future commercialization of a companion diagnostic kit for the NTRK inhibitor VC004.
VC004, a second-generation NTRK inhibitor independently developed by Jiangsu Vcare, has demonstrated excellent in vitro and in vivo activity, favorable pharmacokinetic properties, good tolerability, and high response rates in early clinical studies. With no second-generation NTRK inhibitors currently approved in China, VC004 is poised to fill this critical gap.
Jiangsu Vcare: Specializes in the development of innovative drugs and advanced therapies, with deep expertise in R&D and market expansion across oncology, cardiovascular and cerebrovascular diseases, autoimmune disorders, and other therapeutic areas. The company has developed multiple clinical-stage Class I innovative drugs and clinical solutions.
Geneseeq: A leading Chinese precision oncology testing company, Geneseeq possesses advanced high-throughput gene sequencing technologies and extensive experience in diagnostic kit development and regulatory approval. It is the only domestic enterprise with two NGS-based innovative medical device reagent products.
The partnership will leverage the complementary strengths of both parties to accelerate the development and commercialization of VC004’s companion diagnostics, promote the clinical application of NTRK1/2/3 gene fusion detection, and deliver transformative benefits to cancer patients.
Dr. Gong Yanchun, Co-founder and CEO of Jiangsu Vcare, stated: “VC004, our self-developed next-generation NTRK inhibitor, is currently in a critical Phase II clinical trial in China. We are honored to partner with our ‘neighbor’ Geneseeq at this pivotal stage. Geneseeq has achieved remarkable success in translating gene sequencing technologies into clinical applications. This collaboration will integrate VC004’s research advancements with Geneseeq’s diagnostic expertise, profoundly addressing unmet clinical needs. We look forward to contributing to medical progress and human health through this partnership.”
Dr. Wang Xiaonan, Co-founder and Chief Technology Officer of Geneseeq, remarked: “As fellow enterprises in Nanjing’s Jiangbei New District, Geneseeq and Jiangsu Vcare have collaborated for years. Both companies prioritize innovation, driven by clinical demand, to achieve high-quality development. I am confident that this strategic alliance will accelerate the efficiency of innovative drug R&D and clinical application, ultimately providing patients with more therapeutic options and greater survival benefits.”
Related News
30
2026
/
09
September 29, Jiangsu Vcare PharmaTech Co.,Ltd. (Vcare PharmaTech) and Nanjing Chia-Tai Tianqing Pharmaceutical Company (NJCTTQ) held a signing ceremony in Nanjing. The two parties signed a strategic cooperation agreement for the commercialization of VELMARTO® (Eratrectinib Capsules), a next-generation TRK inhibitor, in mainland China. Under the agreement, Vcare PharmaTech, as the MAHof VELMARTO®, is responsible for clinical development and manufacturing supply; NJCTTQ obtains the exclusive commercialization rights of VELMARTO® within the cooperation territory.
View Details
19
2026
/
08
Recently, Jiangsu Vcare PharmaTech Co., Ltd. (Vcare PharmaTech) announced that the Phase II clinical trial of its self‑developed balanced, highly‑selective new‑generation JAK1 inhibitor VC005 Tablets for oral treatment of alopecia areata has completed enrollment of the first participant. This milestone marks the substantive clinical advancement of another indication of the drug in the autoimmune disease space, bringing expectations for novel therapeutic options for patients with alopecia areata.
View Details
17
2026
/
08
Recently, the Phase III clinical trial of VC005 Tablets, a next‑generation balanced high‑selectivity JAK1 inhibitor independently developed by Jiangsu Vcare PharmaTech Co., Ltd. (Vcare PharmaTech), for the oral treatment of ankylosing spondylitis (AS), has successfully completed enrollment of all subjects.
View Details
13
2026
/
08
Jiangsu Vcare PharmaTech Co., Ltd. (Vcare PharmaTech) recently announced positive top‑line results from its multi‑center, randomized, double‑blind, placebo‑controlled Phase II clinical study evaluating orally‑administered VC005 Tablets, a self‑developed next‑generation balanced highly‑selective JAK1 inhibitor, in adult patients with non‑segmental vitiligo (NSV). This marks another positive top‑line outcome for VC005 Tablets in dermatological indications, following its Phase III program for moderate‑to‑severe atopic dermatitis (AD).
View Details
12
2026
/
08
PanTRKare™ Officially Approved as the Companion Diagnostic for VELMARTO® (Eratrectinib)
August 6，the NMPA granted approval to Geneseeq’s PanTRKare™ NTRK1/2/3 Gene Fusion Detection Kit as a companion diagnostic for VELMARTO® (Eratrectinib), a next‑generation highly selective TRK inhibitor independently developed by Vcare PharmaTech. The approval provides critical support for the precise identification and clinical medication of patients with NTRK fusion‑positive solid tumors.
View Details
17
2026
/
07
Recently, Jiangsu Vcare PharmaTech Co.,Ltd. (Vcare PharmaTech) announced that the pivotal clinical trial of its self-developed Class 1 innovative drug VELMARTO® (generic name: Eratrectinib, research code: VC004) for patients with NTRK fusion-positive solid tumors who failed prior therapies has received official approval. This trial marks the first pivotal clinical study conducted by a China-originated NTRK innovative drug targeting pretreated patients with fusion-positive solid tumors. It signals that VELMARTO® has stepped into a systematic clinical research phase for treating drug-resistant solid tumors, further enriching the evidence-based medical data portfolio of the agent and delivering more robust treatment options for domestic patients with recurrent and drug-resistant NTRK fusion-driven solid tumors.
View Details
Company Address:
No. 136, Huakang Road, Jiangbei New Area, Nanjing, P. R. China
Subsidiary NJVcare Website：
Scan to see
Copyright © JIANGSU VCARE PHARMATECH CO.,LTD.
苏公网安备32011202001742号
Powerby：www.300.cn nanjing.300.cn